Methods: A retrospective analysis of all consecutive PCE studies performed in a tertiary centre between March 2018 and February 2022 in patients with established or suspected CD was undertaken. The Capsule Endoscopy Crohn’s Disease Activity Index (CECDAIic) was used in patients with established CD; this score was compared with clinical features (using the PRO2 questionnaire) and biochemical markers (using C-reactive protein). The percentage of disease upstaging and change in medical management after PCE was also evaluated. Univariate and multivariate binary logistic regression analyses were applied to identify independent predictive factors of treatment intensification.Results: Overall, 67 PCE studies were included - 26(38.8%) for suspected and 41(61.2%) for established CD. CD was confirmed in 8 patients in whom the diagnosis was suspected (32%). Concerning patients with established CD, median CECDAIic was 8 (IQR 14), median C-reactive protein was 4.2 (IQR 6.3) mg/L and median PRO-2 score was 0 (IQR 1). No significant association between CECDALic and PRO2 score (rs=0.182, p=0.261) nor C-reactive protein (rs=0.159, p=0.327) was identified. PCE upstaged Montreal Classification in 6(14.6%) patients, changed disease management in 14(34.1%) and resulted in treatment intensification in 12(29.3%). CECDALIc score was an independent predictor of treatment intensification (p=0.02). On the other hand, disease location and behaviour, presence of L4 disease, PRO-2 score, and C-reactive protein were not.Discussion: This study corroborates the usefulness of PCE in assessing mucosal activity in CD, which was the only independent predictor of treatment intensification, as well as the role of this technique for appropriate disease staging.